These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19061540)

  • 1. Central and peripheral dopamine transporter reduction in Parkinson's disease.
    Buttarelli FR; Capriotti G; Pellicano C; Prosperi D; Circella A; Festa A; Giovannelli M; Tofani A; Pontieri FE; Scopinaro F
    Neurol Res; 2009 Sep; 31(7):687-91. PubMed ID: 19061540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography.
    Im JH; Chung SJ; Kim JS; Lee MC
    J Neurol Sci; 2006 May; 244(1-2):103-9. PubMed ID: 16473371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between the availability of dopamine transporter and olfactory function in healthy subjects.
    Pak K; Kim K; Lee MJ; Lee JM; Kim BS; Kim SJ; Kim IJ
    Eur Radiol; 2018 Apr; 28(4):1756-1760. PubMed ID: 29164380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depressive symptoms in Parkinson's disease are related to reduced [123I]FP-CIT binding in the caudate nucleus.
    Vriend C; Raijmakers P; Veltman DJ; van Dijk KD; van der Werf YD; Foncke EM; Smit JH; Berendse HW; van den Heuvel OA
    J Neurol Neurosurg Psychiatry; 2014 Feb; 85(2):159-64. PubMed ID: 23813742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain.
    Madras BK; Gracz LM; Fahey MA; Elmaleh D; Meltzer PC; Liang AY; Stopa EG; Babich J; Fischman AJ
    Synapse; 1998 Jun; 29(2):116-27. PubMed ID: 9593102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of future weight change with dopamine transporter in patients with Parkinson's disease.
    Pak K; Kim H; Seok JW; Lee MJ; Shin S; Kim K; Lee JM; Seo Y; Kim BS; Jun S; Kim IJ
    J Neural Transm (Vienna); 2019 Jun; 126(6):723-729. PubMed ID: 31102003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years.
    Chouker M; Tatsch K; Linke R; Pogarell O; Hahn K; Schwarz J
    Nucl Med Commun; 2001 Jun; 22(6):721-5. PubMed ID: 11403185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of alpha-dihydroergocryptine and levodopa monotherapy in Parkinson's disease: assessment of changes in DAT binding with [123I]IPT SPECT.
    Pöpperl G; Tatsch K; Ruzicka E; Storch A; Gasser T; Schwarz J
    J Neural Transm (Vienna); 2004 Aug; 111(8):1041-52. PubMed ID: 15254792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease.
    Scherfler C; Seppi K; Mair KJ; Donnemiller E; Virgolini I; Wenning GK; Poewe W
    Brain; 2012 Nov; 135(Pt 11):3348-54. PubMed ID: 23043142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of aging and gender on striatal and extrastriatal [123I]FP-CIT binding in Parkinson's disease.
    Kaasinen V; Joutsa J; Noponen T; Johansson J; Seppänen M
    Neurobiol Aging; 2015 Apr; 36(4):1757-1763. PubMed ID: 25697414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB
    J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased dopamine transporter density in Parkinson's disease patients with Social Anxiety Disorder.
    Moriyama TS; Felicio AC; Chagas MH; Tardelli VS; Ferraz HB; Tumas V; Amaro-Junior E; Andrade LA; Crippa JA; Bressan RA
    J Neurol Sci; 2011 Nov; 310(1-2):53-7. PubMed ID: 21783205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degenerative parkinsonism in patients with psychogenic parkinsonism: A dopamine transporter imaging study.
    Felicio AC; Godeiro-Junior C; Moriyama TS; Shih MC; Hoexter MQ; Borges V; Silva SM; Aguiar Pde C; Andrade LA; Bressan RA; Ferraz HB
    Clin Neurol Neurosurg; 2010 May; 112(4):282-5. PubMed ID: 20061077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced striatal dopamine transporter density associated with working memory deficits in opioid-dependent male subjects: a SPECT study.
    Liang CS; Ho PS; Yen CH; Yeh YW; Kuo SC; Huang CC; Chen CY; Shih MC; Ma KH; Huang SY
    Addict Biol; 2016 Jan; 21(1):196-204. PubMed ID: 25439653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine transporter imaging in autopsy-confirmed Parkinson's disease and multiple system atrophy.
    Perju-Dumbrava LD; Kovacs GG; Pirker S; Jellinger K; Hoffmann M; Asenbaum S; Pirker W
    Mov Disord; 2012 Jan; 27(1):65-71. PubMed ID: 22102521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced striatal dopaminergic innervation shown by IPT and SPECT in patients under neuroleptic treatment: need for levodopa therapy?
    Schwarz J; Scherer J; Trenkwalder C; Mozley PD; Tatsch K
    Psychiatry Res; 1998 Jul; 83(1):23-8. PubMed ID: 9754702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Greater availability of brain dopamine transporters in major depression shown by [99m Tc]TRODAT-1 SPECT imaging.
    Brunswick DJ; Amsterdam JD; Mozley PD; Newberg A
    Am J Psychiatry; 2003 Oct; 160(10):1836-41. PubMed ID: 14514499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No link between striatal dopaminergic axons and dopamine transporter imaging in Parkinson's disease.
    Honkanen EA; Saari L; Orte K; Gardberg M; Noponen T; Joutsa J; Kaasinen V
    Mov Disord; 2019 Oct; 34(10):1562-1566. PubMed ID: 31234224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.